PMID- 26972961
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181202
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 113
DP  - 2016 Mar
TI  - Serum irisin concentrations were increased after transient continuous 
      subcutaneous insulin infusion in type 2 diabetes mellitus patients.
PG  - 44-7
LID - S0168-8227(16)00079-6 [pii]
LID - 10.1016/j.diabres.2016.01.030 [doi]
AB  - Irisin, identified as a novel myokine, plays an important role in improving 
      metabolic disorders, including type 2 diabetes mellitus (T2DM). In this 
      interventional study, we investigated the alteration of serum irisin levels in 
      T2DM subjects after transient continuous subcutaneous insulin infusion (CSII) 
      treatment.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Li, Liang
AU  - Li L
AD  - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, 
      Tongji University, School of Medicine, Shanghai 200072, China.
FAU - Rampersad, Sharvan
AU  - Rampersad S
AD  - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, 
      Tongji University, School of Medicine, Shanghai 200072, China.
FAU - Wang, Xingchun
AU  - Wang X
AD  - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, 
      Tongji University, School of Medicine, Shanghai 200072, China.
FAU - Cheng, Xiaoyun
AU  - Cheng X
AD  - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, 
      Tongji University, School of Medicine, Shanghai 200072, China. Electronic 
      address: chengxiaoyun0210@163.com.
FAU - Qu, Shen
AU  - Qu S
AD  - Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, 
      Tongji University, School of Medicine, Shanghai 200072, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20160202
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Biomarkers)
RN  - 0 (FNDC5 protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibronectins/*blood
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Infusions, Subcutaneous
MH  - Insulin/*administration & dosage
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - CSII
OT  - HbA1c
OT  - Irisin
OT  - Lipid profiles
OT  - T2DM
EDAT- 2016/03/15 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/15 06:00
PHST- 2015/08/13 00:00 [received]
PHST- 2016/01/17 00:00 [revised]
PHST- 2016/01/22 00:00 [accepted]
PHST- 2016/03/15 06:00 [entrez]
PHST- 2016/03/15 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0168-8227(16)00079-6 [pii]
AID - 10.1016/j.diabres.2016.01.030 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2016 Mar;113:44-7. doi: 10.1016/j.diabres.2016.01.030. 
      Epub 2016 Feb 2.